Navigation Links
Angiotech Pharmaceuticals announces FDA approval of TAXUS(R) Liberte(R) Long Stent
Date:7/16/2009

," "expects" and similar expressions, constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and "forward-looking information" within the meaning of applicable Canadian securities laws. All such statements are made pursuant to the "safe harbor" provisions of applicable securities legislation. Forward-looking statements may involve, but are not limited to, comments with respect to our objectives and priorities for 2009 and beyond, our strategies or future actions, our targets, expectations for our financial condition and the results of, or outlook for, our operations, research, development, product and drug development. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Many such risks, uncertainties and other factors are taken into account as part of our assumptions underlying these forward-looking statements and include, among others, the following: general economic and business conditions, both nationally and in the regions in which we operate; market demand; technological changes that could impact our existing products or our ability to develop and commercialize future products; competition; existing governmental regulations and changes in, or the failure to comply with, governmental regulations; adverse results or unexpected delays in pre-clinical and clinical product development processes; adverse findings related to the safety and/or efficacy of our products or products sold by our partners; decisions, and the timing of decisions, made by health regulatory agencies regarding approval of our technology and products; the requirement for substantial funding to conduct research and development and to expand manufacturing and commercialization activities or consummate a
'/>"/>
SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Angiotech Pharmaceuticals, Inc. announces conference call and webcast
2. Angiotech Pharmaceuticals announces FDA 510(k) clearance of the Option(TM) Inferior Vena Cava Filter
3. Angiotech Enters License, Distribution and Supply Agreements for Fibrin and Thrombin Technologies with Haemacure Corporation
4. Angiotech Pharmaceuticals announces FDA approval of next-generation TAXUS(R) Liberte(R) Atom(TM) Stent system
5. Angiotechs corporate partner, Boston Scientific, announces launch of third-generation TAXUS(R) Element(TM) Stent
6. Angiotech launches e-commerce website that allows customers to order Quill(TM) SRS product line
7. Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009
8. Angiotech announces date of annual general meeting of shareholders
9. Angiotech Pharmaceuticals, Inc. Announces Conference Call And Webcast
10. Angiotech Pharmaceuticals, Inc. announces License Agreement with Baxter International Inc.
11. Angiotech announces positive results from Bio-Seal(TM) clinical study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... SANTA BARBARA, Calif. , July 6, 2015 /PRNewswire/ ... virus that is integrated into their chromosomes. These individuals ... to a new study published in one of the ... Laval Faculty of Medicine in Canada.  Photo ... known as human herpesvirus 6 (HHV-6) causes roseola (also ...
(Date:7/6/2015)... , June 29, 2015 ... announced the addition of the "Biotechnology for ... Biotechnology for the Non-Biotechnologist, ideal for non-Scientists ... principles, techniques and potential of biotechnology. ... the basic theory, principles, techniques, and potential of ...
(Date:7/6/2015)... 2015 ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: ... Novella Clinical (Novella), to conduct the phase ... diagnosed glioblastoma. Novella is a full-service, global clinical research ... mid-sized oncology companies. The ICT-107 phase 3 trial will ... Europe and Canada ...
(Date:7/3/2015)... WIEN , July 3, ... Tiedemiehet voivat hakea verkossa osoitteessa  ... for Open Innovation in Science" ... Ludwig Boltzmann Gesellschaftin (LBG) tekemän, ... tutkimuksen mukaan terveystieteiden kaksi suurinta ...
Breaking Biology Technology:Inherited Herpes Virus Increases the Risk of Angina Reports HHV-6 Foundation 2Inherited Herpes Virus Increases the Risk of Angina Reports HHV-6 Foundation 3ImmunoCellular Therapeutics Establishes Agreement with Novella Clinical to Conduct ICT-107 Phase 3 Registration Trial in Glioblastoma 2Maailman ensimmäinen tiedemiesten koulutukseen suunniteltu avoimen innovaation ohjelma käynnistyy 2Maailman ensimmäinen tiedemiesten koulutukseen suunniteltu avoimen innovaation ohjelma käynnistyy 3
... Cambridge, Mass. -- May 19, 2008 -- ... have demonstrated the first room-temperature electrically-pumped semiconductor ... known as T-rays. The breakthrough in laser ... the potential to become a standard Terahertz ...
... platform expected to enable, Volcano to offer an expanded ... ... SAN DIEGO, May 19 Volcano Corporation,(Nasdaq: VOLC ), ... Tomography (OCT) products designed,to enhance the diagnosis and treatment of coronary ...
... of Ablation Therapy Using HALO System Demonstrated for, ... Progression, SAN DIEGO, May 19 Booth ... a technology leader in the design and manufacture,of ... presentation,of a landmark study entitled, "A Randomized, Multicenter, ...
Cached Biology Technology:Engineers demonstrate first room-temperature semiconductor source of coherent Terahertz radiation 2Volcano Announces Acquisition of Novelis, Inc. 2Volcano Announces Acquisition of Novelis, Inc. 3Volcano Announces Acquisition of Novelis, Inc. 4Volcano Announces Acquisition of Novelis, Inc. 5Volcano Announces Acquisition of Novelis, Inc. 6Volcano Announces Acquisition of Novelis, Inc. 7Presentation of Landmark Clinical Trial Evaluating Endoscopic Treatment for Pre-cancerous Condition of Esophagus 2Presentation of Landmark Clinical Trial Evaluating Endoscopic Treatment for Pre-cancerous Condition of Esophagus 3
(Date:6/25/2015)... PRINCETON, N.J. , June 25, 2015  TAKE ... awarded a patent by the United States Patent and ... Data Standardization". This process leverages TAKE Solutions, Clinical Accelerators ... by over 50% (when compared to standardization without the ... At the heart ...
(Date:6/24/2015)... , June 24, 2015  Synaptics Inc. ... human interface solutions, today announced that Sharp has ... provide secure authentication for its latest flagship smartphone ... more than 200 million shipments of its fingerprint ... reinforces Synaptics, strength, scalability and leadership in the ...
(Date:6/23/2015)... Minn. , June 23, 2015   ... company that supports the entire spectrum of clinical ... iMedNet ™ , the company,s intuitive, ... been awarded a Silver 2015 Stevie® Award by ... Health Products & Services Website category.  The American ...
Breaking Biology News(10 mins):TAKE Solutions Awarded Patent By USPTO 2Synaptics Brings Natural ID Technology to Sharp's Newest Flagship Smartphone 2MedNet Solutions' iMedNet eClinical Wins Silver Stevie Award 2
... bacteria which can grow on and 'mop up' smelly ... breath. These smelly, highly reactive 'one-carbon' compounds are naturally ... the mouth. , Dr Ann Wood and her colleagues ... August issue of Environmental Microbiology. The odour-eating methylotrophic bacteria ...
... Forest University School of Medicine have successfully isolated stem cells ... them into becoming fat, muscle and bone cells. The study, ... a single adult stem cell to become multiple tissue types, ... cells should provide a valuable resource for tissue repair and ...
... engineers has demonstrated for the first time that it is ... of the body and use it to repair damaged bone ... on a dramatic departure from the current practice in tissue ... of organs: The bone bioreactor" published online next week by ...
Cached Biology News:Researchers grow stem cells from human skin 2New method shows it is possible to grow bone for grafts within a patient's body 2New method shows it is possible to grow bone for grafts within a patient's body 3
... Disruption of the mitochondrial transmembrane potential ... events that occur following induction of ... Kit utilizes a lipophilic cation, termed ... marker. MitoLight is a mitochondrial dye ...
Liquid. 50 μg/ml in PBS, pH 7.4. PROTECT FROM LIGHT. A convenient form of propidium iodide useful for flow cytometry studies. RTECS SF7949600, CAS 25535-16-4, M.W. 668.4. ...
... The Poly-Caspases FLICA Apoptosis Detection Kit contains ... a carboxyfluorescein (FAM) derivative of valylalanylaspartic acid ... of caspase activity. When added to ... probe enters each cell and covalently binds ...
Lyophilized solid. Suitable for evaluating functional activity of human complement components and for other research requiring a high level of hemolytic activity. ...
Biology Products: